[go: up one dir, main page]

WO2004020577A3 - Procedes permettant d'inhiber l'expression de genes au moyen de polynucleotides - Google Patents

Procedes permettant d'inhiber l'expression de genes au moyen de polynucleotides Download PDF

Info

Publication number
WO2004020577A3
WO2004020577A3 PCT/US2003/015643 US0315643W WO2004020577A3 WO 2004020577 A3 WO2004020577 A3 WO 2004020577A3 US 0315643 W US0315643 W US 0315643W WO 2004020577 A3 WO2004020577 A3 WO 2004020577A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
polynucleotides
processes
inhibiting gene
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/015643
Other languages
English (en)
Other versions
WO2004020577A2 (fr
Inventor
David L Lewis
David B Rozema
Jon A Wolff
James E Hagstrom
Hans Herweijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Madison Inc
Original Assignee
Mirus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirus Corp filed Critical Mirus Corp
Priority to EP03751760A priority Critical patent/EP1506020A4/fr
Publication of WO2004020577A2 publication Critical patent/WO2004020577A2/fr
Publication of WO2004020577A3 publication Critical patent/WO2004020577A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé permettant d'inhiber l'expression d'un gène spécifique dans une cellule animale par administration d'une combinaison d'inhibiteurs de la fonction de l'ARN. L'utilisation d'une combinaison d'inhibiteurs permet d'améliorer l'efficacité d'inhibition de l'expression de gènes. Ce procédé peut être utilisé pour réduire l'expression de gènes dans des cellules in vitro et in vivo.
PCT/US2003/015643 2002-05-23 2003-05-19 Procedes permettant d'inhiber l'expression de genes au moyen de polynucleotides Ceased WO2004020577A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03751760A EP1506020A4 (fr) 2002-05-23 2003-05-19 Procedes permettant d'inhiber l'expression de genes au moyen de polynucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38284202P 2002-05-23 2002-05-23
US60/382,842 2002-05-23

Publications (2)

Publication Number Publication Date
WO2004020577A2 WO2004020577A2 (fr) 2004-03-11
WO2004020577A3 true WO2004020577A3 (fr) 2004-09-23

Family

ID=31978209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/015643 Ceased WO2004020577A2 (fr) 2002-05-23 2003-05-19 Procedes permettant d'inhiber l'expression de genes au moyen de polynucleotides

Country Status (2)

Country Link
EP (1) EP1506020A4 (fr)
WO (1) WO2004020577A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081628A2 (fr) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
WO2002097114A2 (fr) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Traitement a l'acide nucleique de maladies ou d'affections associees aux taux de ras, her2 et hiv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUNTER ET AL: "Genetics: A touch of elegance with RNAi", CURR. BIOLOGY, vol. 9, no. 12, June 1999 (1999-06-01), pages R440 - R442, XP002211290 *
See also references of EP1506020A4 *
SIROIS ET AL: "Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening", CIRCULATION, vol. 95, no. 3, 4 February 1997 (1997-02-04), pages 669 - 676, XP002967163 *

Also Published As

Publication number Publication date
EP1506020A2 (fr) 2005-02-16
EP1506020A4 (fr) 2007-08-29
WO2004020577A2 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2003080794A3 (fr) Inhibition de la fonction d'arn par delivrance d'inhibiteurs dans des cellules animales
WO2005009346A3 (fr) Inhibition d'une fonction genique par distribution in vivo d'inhibiteurs d'expression genique a base de polynucleotides dans des cellules mammiferes
MXPA02004233A (es) Produccion ginogenetica o androgenetica de celulas pluripotentes y lineas celulares, y uso de las mismas para producir celulas diferenciadas y tejidos.
MXPA06010900A (es) Inhibidores de histona desacetilasa.
WO2004065564A3 (fr) Activation electromagnetique d'expression genetique et de croissance cellulaire
GB0007371D0 (en) Chemical compounds
GEP20084395B (en) PYRROLO [3,4-c] PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
IL158543A0 (en) Homing of embryonic stem cells to a target zone in tissue using active therapeutics of substances
WO2004050826A3 (fr) Procede de mise en culture dynamique de cellules souches embryonnaires
WO2007100895A3 (fr) Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
AU2003221584A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
IL173236A0 (en) Plant cell cycle genes and methods of use
AU3772000A (en) Selective inhibition of cyclooxygenase-2
AUPS112802A0 (en) Methods of inducing differentiation of stem cells into a specific cell lineage
ATE446373T1 (de) Sequenz-spezifische dna-rekombination in eukaryotischen zellen
WO2004072248A3 (fr) Processus d'administration de sirna a un tissu de muscle cardiaque
WO2005017098A3 (fr) Compositions et methodes utilisant un arnsi, des composes amphipathiques et des polycations
WO2009072635A1 (fr) Procédé pour amplifier des cellules souches hématopoïétiques utilisant un composé hétérocyclique
WO2009072625A1 (fr) Procédé d'amplification de cellules souches hématopoïétiques avec un composé hétérocyclique
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
WO2000047231A3 (fr) Nouvelle inhibition antisens de rad51
WO2004020577A3 (fr) Procedes permettant d'inhiber l'expression de genes au moyen de polynucleotides
WO2004003152A3 (fr) Inhibiteurs de sos1
MXPA05011435A (es) 5-hidroxiindoles con grupos de n-oxido y su uso como inhibidores de fosfodiesterasa 4.
WO2003099228A8 (fr) Compositions et procedes d'inhibition de l'expression genetique au moyen de polynucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003751760

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003751760

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP